Skip to main content

Advertisement

SpringerLink
Log in

Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review

  • Review
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Purpose

Psoriasis is an inflammatory disease characterized by skin thickening with silvery white desquamation due to dysregulated inflammatory pathways and elevated levels of inflammatory cytokines. Biologic agents targeting these inflammatory cytokines have brought about significant improvement in clearing psoriatic lesions in patients with moderate-to-severe psoriasis. Moreover, biologics exert both beneficial and detrimental effects on comorbidities in psoriasis, which include increased risk of cardiovascular events, metabolic syndrome, among other conditions. However, non-immune functions of cytokines targeted by biologics, and, hence, the potential risks and benefits of biologics for psoriasis to different organs/systems and comorbidities, have not been well elucidated.

Results

This review summarizes current understanding of the pathogenesis of psoriasis-related comorbidities and emerging discoveries of roles of cytokines targeted in psoriasis treatment, including tumor necrosis factor α and interleukins 12, 23, and 17, aiming to complete the safety profile of each biologics and provide therapeutic implications on psoriasis-related comorbidities, and on diseases involving other organs or systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wang TS, Hsieh CF, Tsai TF. Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: a nationwide, population-based observational study in Taiwan. J Dermatol Sci. 2016;84:340–5.

    PubMed  Google Scholar 

  2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:205–12.

    CAS  PubMed  Google Scholar 

  3. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–6.

    PubMed  Google Scholar 

  4. Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178:854–62.

    CAS  PubMed  Google Scholar 

  5. Wang TS, Chiu HY, Hong JB, Chan CC, Lin SJ, Tsai TF. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016;308:55–63.

    CAS  PubMed  Google Scholar 

  6. Huang YW, Tsai TF. HLA-Cw1 and Psoriasis. Am J Clin Dermatol. 2021;22:339–47.

    PubMed  Google Scholar 

  7. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301–15.

    CAS  PubMed  Google Scholar 

  8. Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628–37.

    CAS  PubMed  Google Scholar 

  9. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182:840–8.

    CAS  PubMed  Google Scholar 

  10. Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183:638–49.

    CAS  PubMed  Google Scholar 

  11. Ahlehoff O, Gislason GH, Charlot M, Jørgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147–57.

    CAS  PubMed  Google Scholar 

  12. Li WQ, Han JL, Manson JE, Rimm EB, Rexrode KM, Curhan GC, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol. 2012;166:811–8.

    PubMed  Google Scholar 

  13. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(775):e1-6.

    Google Scholar 

  14. Jung KJ, Kim TG, Lee JW, Lee M, Oh J, Lee SE, et al. Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: A 15-year nationwide population-based cohort study. J Dermatol. 2019;46:859–66.

    PubMed  Google Scholar 

  15. Chiu H-Y, Chang W-L, Shiu M-N, Huang W-F, Tsai T-F. Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: a nationwide cohort study. J Dermatol. 2018;45:1381–8.

    PubMed  Google Scholar 

  16. Khalid U, Ahlehoff O, Gislason GH, Kristensen SL, Skov L, Torp-Pedersen C, et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail. 2014;16:743–8.

    PubMed  Google Scholar 

  17. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–41.

    CAS  PubMed  Google Scholar 

  18. Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12–29.

    PubMed  Google Scholar 

  19. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133:2340–6.

    CAS  PubMed  Google Scholar 

  20. Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20:513–28.

    CAS  PubMed  Google Scholar 

  21. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens. 2001;14:44s–54s.

    CAS  PubMed  Google Scholar 

  23. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007;157:1249–51.

    CAS  PubMed  Google Scholar 

  24. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68–73.

    CAS  PubMed  Google Scholar 

  25. van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol. 2014;70:517–24.

    PubMed  Google Scholar 

  26. Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156:421–9.

    PubMed  PubMed Central  Google Scholar 

  27. Egeberg A, Mallbris L, Warren RB, Bachelez H, Gislason GH, Hansen PR, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016;175:487–92.

    CAS  PubMed  Google Scholar 

  28. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Wang J, Ke R, Shi W, Yan X, Wang Q, Zhang Q, et al. Association between psoriasis and asthma risk: a meta-analysis. Allergy Asthma Proc. 2018;39:103–9.

    PubMed  PubMed Central  Google Scholar 

  30. Busse WW. Asthma and psoriasis: what do they have in common? IL-17A! J Allergy Clin Immunol. 2019;144:1169–71.

    PubMed  Google Scholar 

  31. Wang CQF, Akalu YT, Suarez-Farinas M, Gonzalez J, Mitsui H, Lowes MA, et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol. 2013;133:2741–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Chiu HY, Chang Liao NF, Hui RC, Lin YJ, Tsai YC, Huang YH. Measurement and prediction of the severity of postinflammatory dyspigmentation after resolution of psoriatic plaques in patients treated with biologic therapy. J Am Acad Dermatol. 2021. https://doi.org/10.1016/j.jaad.2021.02.010.

    Article  PubMed  Google Scholar 

  33. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134:1542–51.

    CAS  PubMed  Google Scholar 

  34. Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29:1063–70.

    CAS  PubMed  Google Scholar 

  35. Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol. 2017;31:798–807.

    CAS  PubMed  Google Scholar 

  36. Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld LE, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29:1128–34.

    CAS  PubMed  Google Scholar 

  37. Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15:45–50.

    PubMed  Google Scholar 

  38. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244–50.

    CAS  PubMed  Google Scholar 

  39. Wu JJ, Joshi AA, Reddy SP, Batech M, Egeberg A, Ahlehoff O, et al. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol. 2018;32:1320–6.

    CAS  PubMed  Google Scholar 

  40. Bissonnette R, Harel F, Krueger JG, Guertin MC, Chabot-Blanchet M, Gonzalez J, et al. TNF-α antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol. 2017;137:1638–45.

    CAS  PubMed  Google Scholar 

  41. Genre F, Armesto S, Corrales A, López-Mejías R, Remuzgo-Martínez S, Pina T, et al. Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2017;28:726–30.

    CAS  PubMed  Google Scholar 

  42. Gkalpakiotis S, Arenbergerova M, Gkalpakioti P, Potockova J, Arenberger P, Kraml P. Long-term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: results of a 2 year study. Dermatol Ther. 2020;33: e14110.

    CAS  PubMed  Google Scholar 

  43. Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 2011;36:845–50.

    CAS  PubMed  Google Scholar 

  44. Sigurdardottir G, Ekman AK, Ståhle M, Bivik C, Enerbäck C. Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis. J Am Acad Dermatol. 2014;70:1067–75.

    CAS  PubMed  Google Scholar 

  45. Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159:322–30.

    CAS  PubMed  Google Scholar 

  46. Campanati A, Ganzetti G, Giuliodori K, Marra M, Bonfigli A, Testa R, et al. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis. Int J Dermatol. 2015;54:839–45.

    CAS  PubMed  Google Scholar 

  47. Pelletier F, Garnache-Ottou F, Biichlé S, Vivot A, Humbert P, Saas P, et al. Effects of anti-TNF-α agents on circulating endothelial-derived and platelet-derived microparticles in psoriasis. Exp Dermatol. 2014;23:924–5.

    CAS  PubMed  Google Scholar 

  48. Ríos-Navarro C, de Pablo C, Collado-Diaz V, Orden S, Blas-Garcia A, Martínez-Cuesta MÁ, et al. Differential effects of anti-TNF-α and anti-IL-12/23 agents on human leukocyte–endothelial cell interactions. Eur J Pharmacol. 2015;765:355–65.

    PubMed  Google Scholar 

  49. Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC. Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging. 2013;6:83–90.

    PubMed  Google Scholar 

  50. Pina T, Corrales A, Lopez-Mejias R, Armesto S, Gonzalez-Lopez MA, Gómez-Acebo I, et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: a 6-month prospective study. J Dermatol. 2016;43:1267–72.

    CAS  PubMed  Google Scholar 

  51. Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, et al. Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2016;30:92–5.

    CAS  PubMed  Google Scholar 

  52. Pina T, Armesto S, Lopez-Mejias R, Genre F, Ubilla B, Gonzalez-Lopez MA, et al. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2015;29:1325–30.

    CAS  PubMed  Google Scholar 

  53. Wu JJ, Tsai TF. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol. 2008;144:1403–4.

    PubMed  Google Scholar 

  54. Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H. Impact of TNF-α inhibitors on body weight and BMI: a systematic review and meta-analysis. Front Pharmacol. 2020;11:481.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22:341–4.

    CAS  PubMed  Google Scholar 

  56. Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther. 2011;24:446–51.

    PubMed  Google Scholar 

  57. Florin V, Cottencin AC, Delaporte E, Staumont-Sallé D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol. 2013;27:e186–90.

    CAS  PubMed  Google Scholar 

  58. Mahé E, Reguiai Z, Barthelemy H, Quiles-Tsimaratos N, Chaby G, Girard C, et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol. 2014;28:151–9.

    PubMed  Google Scholar 

  59. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008;103:1036–42.

    CAS  PubMed  Google Scholar 

  60. Klujszo EH, Parcheta P, Witkowska AB, Krecisz B. Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications. Postepy Dermatol Alergol. 2020;37:468–74.

    PubMed  Google Scholar 

  61. Di Minno MN, Iervolino S, Peluso R, Russolillo A, Lupoli R, Scarpa R, et al. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. J Rheumatol. 2012;39:1042–6.

    PubMed  Google Scholar 

  62. Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, et al. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015;27:1154–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Rossi RE, Parisi I, Despott EJ, Burroughs AK, O’Beirne J, Conte D, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol. 2014;20:17352–9.

    PubMed  PubMed Central  Google Scholar 

  64. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5:193–200.

    PubMed  Google Scholar 

  65. Wu CY, Chang YT, Juan CK, Shen JL, Lin YP, Shieh JJ, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore). 2016;95: e3816.

    CAS  Google Scholar 

  66. Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using (18)F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol. 2019;80:1322–31.

    CAS  PubMed  Google Scholar 

  67. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–28.

    CAS  PubMed  Google Scholar 

  68. Kisielnicka A, Szczerkowska-Dobosz A, Nowicki RJ. The influence of body weight of patients with chronic plaque psoriasis on biological treatment response. Postepy Dermatol Alergol. 2020;37:168–73.

    PubMed  PubMed Central  Google Scholar 

  69. Umezawa Y, Saeki H, Nakagawa H. Some clinical factors affecting quality of the response to ustekinumab for psoriasis. J Dermatol. 2014;41:690–6.

    CAS  PubMed  Google Scholar 

  70. Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175:340–7.

    CAS  PubMed  Google Scholar 

  71. Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013;168:1124–7.

    CAS  PubMed  Google Scholar 

  72. Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses. J Am Acad Dermatol. 2013;68:863–5.

    CAS  PubMed  Google Scholar 

  73. Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14:706–14.

    CAS  PubMed  Google Scholar 

  74. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844–54.

    CAS  PubMed  Google Scholar 

  75. Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, et al. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol. 2020;34:769–78.

    CAS  PubMed  Google Scholar 

  76. Poizeau F, Nowak E, Kerbrat S, Le Nautout B, Droitcourt C, Drici MD, et al. Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab. JAMA Dermatol. 2020;156:1208–15.

    PubMed  Google Scholar 

  77. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74.

    CAS  PubMed  Google Scholar 

  78. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–84.

    CAS  PubMed  Google Scholar 

  79. Llamas-Velasco M, Concha-Garzón MJ, García-Diez A, Daudén E. Liver injury in psoriasis patients receiving ustekinumab: a retrospective study of 44 patients treated in the clinical practice setting. Actas Dermosifiliogr. 2015;106:470–6.

    CAS  PubMed  Google Scholar 

  80. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 1997;71:3236–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest. 1997;99:3025–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169:1295–303.

    CAS  PubMed  Google Scholar 

  83. Ting SW, Chen YC, Huang YH. Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab. Clin Drug Investig. 2018;38:873–80.

    CAS  PubMed  Google Scholar 

  84. Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, et al. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019;3:30.

    PubMed  PubMed Central  Google Scholar 

  85. Rahman PHP, Deodhar A, Kollmeier A, Hsia E, Zhou B, Lin X, Han C, Mease P. In two phase-3 trials, guselkumab reduced fatigue over 52 weeks in patients with psoriatic arthritis and demonstrated independent treatment effects on fatigue after adjustment for clinical response (ACR20) [abstract]. Arthritis Rheumatol. 2020;2020:72.

    Google Scholar 

  86. Egeberg A, Wu JJ, Korman N, Solomon JA, Goldblum O, Zhao F, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018;79:104-109.e8.

    CAS  PubMed  Google Scholar 

  87. Takamura S, Takahashi A, Inoue Y, Teraki Y. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis. J Dermatol. 2018;45:1130–4.

    CAS  PubMed  Google Scholar 

  88. Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015;16:323–30.

    PubMed  Google Scholar 

  89. Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71:1176–82.

    CAS  PubMed  Google Scholar 

  90. Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2020;34:533–41.

    CAS  PubMed  Google Scholar 

  91. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177:47–62.

    CAS  PubMed  Google Scholar 

  92. Xu R, Tao A, Zhang S, Zhang M. Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice. Acta Biochim Biophys Sin (Shanghai). 2013;45:726–33.

    CAS  Google Scholar 

  93. Romanatto T, Cesquini M, Amaral ME, Roman EA, Moraes JC, Torsoni MA, et al. TNF-alpha acts in the hypothalamus inhibiting food intake and increasing the respiratory quotient–effects on leptin and insulin signaling pathways. Peptides. 2007;28:1050–8.

    CAS  PubMed  Google Scholar 

  94. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48.

    PubMed  PubMed Central  Google Scholar 

  95. Lorenzo M, Fernández-Veledo S, Vila-Bedmar R, Garcia-Guerra L, De Alvaro C, Nieto-Vazquez I. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. J Anim Sci. 2008;86:E94-104.

    CAS  PubMed  Google Scholar 

  96. Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun. 2010;11:145–56.

    CAS  PubMed  Google Scholar 

  97. Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil GS. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes. 2002;51:1876–83.

    CAS  PubMed  Google Scholar 

  98. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96:E146–50.

    CAS  PubMed  Google Scholar 

  99. de Boer OJ, Li X, Teeling P, Mackaay C, Ploegmakers HJ, van der Loos CM, et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost. 2013;109:290–7.

    PubMed  Google Scholar 

  100. Erbel C, Akhavanpoor M, Okuyucu D, Wangler S, Dietz A, Zhao L, et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol. 2014;193:4344–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. van Es T, van Puijvelde GH, Ramos OH, Segers FM, Joosten LA, van den Berg WB, et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun. 2009;388:261–5.

    PubMed  Google Scholar 

  102. Xie JJ, Wang J, Tang TT, Chen J, Gao XL, Yuan J, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine. 2010;49:185–93.

    CAS  PubMed  Google Scholar 

  103. Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34:570–7.

    CAS  PubMed  Google Scholar 

  104. Gisterå A, Robertson AK, Andersson J, Ketelhuth DF, Ovchinnikova O, Nilsson SK, et al. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med. 2013;5: 196ra100.

    PubMed  Google Scholar 

  105. Giles DA, Moreno-Fernandez ME, Divanovic S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets. 2015;16:1315–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  106. Harley IT, Stankiewicz TE, Giles DA, Softic S, Flick LM, Cappelletti M, et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology. 2014;59:1830–9.

    CAS  PubMed  Google Scholar 

  107. Tobinick E. Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res. 2007;4:550–2.

    CAS  PubMed  Google Scholar 

  108. Dalton B, Bartholdy S, Robinson L, Solmi M, Ibrahim MAA, Breen G, et al. A meta-analysis of cytokine concentrations in eating disorders. J Psychiatr Res. 2018;103:252–64.

    PubMed  Google Scholar 

  109. Imokawa G. Melanocyte activation mechanisms and rational therapeutic treatments of solar lentigos. Int J Mol Sci. 2019;20:3666.

    CAS  PubMed Central  Google Scholar 

  110. Kostic M, Dzopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stojanovic I, et al. IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol. 2014;79:181–6.

    CAS  PubMed  Google Scholar 

  111. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8:500–8.

    CAS  PubMed  Google Scholar 

  112. Havrdová E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263:1287–95.

    PubMed  Google Scholar 

  113. Al-Ayadhi LY, Mostafa GA. Elevated serum levels of interleukin-17A in children with autism. J Neuroinflammation. 2012;9:158.

    CAS  PubMed  PubMed Central  Google Scholar 

  114. AshwoodWills PS, Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol. 2006;80:1–15.

    Google Scholar 

  115. Atladóttir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics. 2009;124:687–94.

    PubMed  Google Scholar 

  116. Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016;351:933–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Kugelberg E. Neuroimmunology: IL-17A mediates a path to autism. Nat Rev Immunol. 2016;16:205.

    CAS  PubMed  Google Scholar 

  118. van der Zwaag B, Franke L, Poot M, Hochstenbach R, Spierenburg HA, Vorstman JA, et al. Gene-network analysis identifies susceptibility genes related to glycobiology in autism. PLoS ONE. 2009;4: e5324.

    PubMed  PubMed Central  Google Scholar 

  119. Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood. 2012;120:3793–802.

    CAS  PubMed  Google Scholar 

  120. Li GZ, Zhong D, Yang LM, Sun B, Zhong ZH, Yin YH, et al. Expression of interleukin-17 in ischemic brain tissue. Scand J Immunol. 2005;62:481–6.

    CAS  PubMed  Google Scholar 

  121. Meeuwsen S, Persoon-Deen C, Bsibsi M, Ravid R, van Noort JM. Cytokine, chemokine and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuli. Glia. 2003;43:243–53.

    PubMed  Google Scholar 

  122. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31:331–41.

    CAS  PubMed  Google Scholar 

  123. Oberstein TJ, Taha L, Spitzer P, Hellstern J, Herrmann M, Kornhuber J, et al. Imbalance of circulating T(h)17 and regulatory T cells in Alzheimer’s disease: a case control study. Front Immunol. 2018;9:1213.

    PubMed  PubMed Central  Google Scholar 

  124. Chen JM, Jiang GX, Li QW, Zhou ZM, Cheng Q. Increased serum levels of interleukin-18, -23 and -17 in Chinese patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2014;38:321–9.

    CAS  PubMed  Google Scholar 

  125. Paller AS, Renert-Yuval Y, Suprun M, Esaki H, Oliva M, Huynh TN, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139:152–65.

    CAS  PubMed  Google Scholar 

  126. Bhardwaj S, Bhatia A, Kumaran MS, Parsad D. Role of IL-17A receptor blocking in melanocyte survival: a strategic intervention against vitiligo. Exp Dermatol. 2019;28:682–9.

    CAS  PubMed  Google Scholar 

  127. Kotobuki Y, Tanemura A, Yang L, Itoi S, Wataya-Kaneda M, Murota H, et al. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res. 2012;25:219–30.

    CAS  PubMed  Google Scholar 

  128. Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS ONE. 2011;6: e18907.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Wasilewska A, Winiarska M, Olszewska M, Rudnicka L. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol. 2016;33:247–52.

    PubMed  PubMed Central  Google Scholar 

  130. Bălănescu P, Lădaru A, Voiosu T, Nicolau A, Ene M, Bălănescu E. Th17 and IL-17 immunity in chronic hepatitis C infection. Rom J Intern Med. 2012;50:13–8.

    PubMed  Google Scholar 

  131. Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol. 2013;8:40.

    CAS  PubMed  PubMed Central  Google Scholar 

  132. Fábrega E, López-Hoyos M, San Segundo D, Casafont F, Pons-Romero F. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl. 2009;15:629–33.

    PubMed  Google Scholar 

  133. Lan RY, Salunga TL, Tsuneyama K, Lian ZX, Yang GX, Hsu W, et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun. 2009;32:43–51.

    CAS  PubMed  Google Scholar 

  134. Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology. 2009;49:646–57.

    CAS  PubMed  Google Scholar 

  135. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980–9.

    CAS  PubMed  Google Scholar 

  136. Tan X, Sun S, Liu Y, Zhu T, Wang K, Ren T, et al. Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome. Eye (Lond). 2014;28:608–13.

    CAS  Google Scholar 

  137. Das Sarma J, Ciric B, Marek R, Sadhukhan S, Caruso ML, Shafagh J, et al. Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2009;6:14.

    PubMed  Google Scholar 

  138. Elain G, Jeanneau K, Rutkowska A, Mir AK, Dev KK. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62:725–35.

    PubMed  Google Scholar 

  139. Atladóttir HO, Thorsen P, Østergaard L, Schendel DE, Lemcke S, Abdallah M, et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord. 2010;40:1423–30.

    PubMed  Google Scholar 

  140. Fang SY, Wang S, Huang N, Yeh HH, Chen CY. Prenatal infection and autism spectrum disorders in childhood: a population-based case-control study in Taiwan. Paediatr Perinat Epidemiol. 2015;29:307–16.

    PubMed  Google Scholar 

  141. Erbel C, Dengler TJ, Wangler S, Lasitschka F, Bea F, Wambsganss N, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol. 2011;106:125–34.

    CAS  PubMed  Google Scholar 

  142. Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res. 2008;49:697–714.

    CAS  PubMed  Google Scholar 

  143. Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N, et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol. 2014;134:2757–67.

    CAS  PubMed  Google Scholar 

  144. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677–87.

    CAS  PubMed  Google Scholar 

  145. Digiovanna JJ, Mauro T, Milstone LM, Schmuth M, Toro JR. Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther. 2013;26:26–38.

    PubMed  Google Scholar 

  146. Hernández-Martin A, Aranegui B, Martin-Santiago A, Garcia-Doval I. A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris. J Am Acad Dermatol. 2013;69:544-549.e8.

    PubMed  Google Scholar 

  147. Fontao L, Laffitte E, Briot A, Kaya G, Roux-Lombard P, Fraitag S, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol. 2011;131:1947–50.

    CAS  PubMed  Google Scholar 

  148. Zhou J, An X, Dong J, Wang Y, Zhong H, Duan L, et al. IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo. FASEB J. 2018;32:4899–916.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors received no specific funding for this work. The authors declare no conflicts of interest nor competing interest.

Funding

The authors received no specific funding for this work.

Author information

Authors and Affiliations

  1. Department of Medical Education, National Taiwan University Hospital, Taipei, Taiwan

    Tung-Lin Lee

  2. Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, 7 Chung-Shan S. Rd., Taipei, 100, Taiwan

    Tsen-Fang Tsai

Authors
  1. Tung-Lin Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsen-Fang Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsen-Fang Tsai.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest nor competing interest.

Additional information

Responsible Editor: John Di Battista.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, TL., Tsai, TF. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review. Inflamm. Res. 71, 157–168 (2022). https://doi.org/10.1007/s00011-021-01528-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-021-01528-0

Keywords

Search

Navigation